
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


Lixte Biotechnology Holdings Inc (LIXT)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: LIXT (1-star) is a SELL. SELL since 1 days. Profits (-7.11%). Updated daily EoD!
Analysis of Past Performance
Type Stock | Historic Profit -70.62% | Avg. Invested days 24 | Today’s Advisory SELL |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.97M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.37 | 52 Weeks Range 0.64 - 3.00 | Updated Date 06/30/2025 |
52 Weeks Range 0.64 - 3.00 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.45 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -81.14% | Return on Equity (TTM) -155.14% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4085448 | Price to Sales(TTM) - |
Enterprise Value 4085448 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.5 | Shares Outstanding 2756990 | Shares Floating 2527941 |
Shares Outstanding 2756990 | Shares Floating 2527941 | ||
Percent Insiders 18.43 | Percent Institutions 15.84 |
Upturn AI SWOT
Lixte Biotechnology Holdings Inc

Company Overview
History and Background
Lixte Biotechnology Holdings Inc. was founded in 2005. It is a biotechnology company focused on developing cancer treatments, particularly through the use of protein phosphatase inhibitors. Key milestones include preclinical and clinical trials of its lead compound, LB-100.
Core Business Areas
- Drug Development: Focused on developing and commercializing novel therapies for cancer and other diseases.
Leadership and Structure
Dr. John S. Kovach is the CEO of Lixte Biotechnology Holdings Inc. The company operates with a small management team and collaborates with research institutions for drug development.
Top Products and Market Share
Key Offerings
- LB-100: LB-100 is Lixte's lead compound, a protein phosphatase 2A (PP2A) inhibitor in clinical development for various cancers. Market share data is not readily available as it is still in clinical trials. Competitors in the PP2A inhibition space are emerging, but LB-100 is among the more advanced clinically. Competitors include companies developing other protein phosphatase inhibitors or therapies targeting similar cancer pathways.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, with significant investment in research and development. The oncology market is growing due to an aging population and advances in cancer diagnostics and treatment.
Positioning
Lixte is a small biotechnology company focusing on a specific therapeutic approach (PP2A inhibition). Its competitive advantage lies in its proprietary compounds and clinical data, though its size limits its resources compared to larger pharmaceutical companies.
Total Addressable Market (TAM)
The total addressable market for cancer therapies is estimated in the hundreds of billions of dollars globally. Lixte's positioning depends on the success of LB-100 and its ability to capture a share of specific cancer treatment markets.
Upturn SWOT Analysis
Strengths
- Proprietary compounds
- Focus on a specific therapeutic target (PP2A inhibition)
- Early-stage clinical data showing promise
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on a single lead compound (LB-100)
- Small company size relative to competitors
- High risk associated with drug development
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of LB-100 into additional cancer indications
- Positive clinical trial results
- Potential for breakthrough therapy designation
Threats
- Clinical trial failures
- Competition from other cancer therapies
- Regulatory hurdles
- Funding challenges
Competitors and Market Share
Key Competitors
- MRNA
- PFE
- JNJ
Competitive Landscape
Lixte faces significant competition from larger pharmaceutical companies with greater resources. Its advantage lies in its specific therapeutic target and potential for a novel treatment approach. Lixte is disadvantaged due to its smaller size, limited financial resources, and dependence on the success of its lead compound.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily driven by research and development progress rather than revenue generation.
Future Projections: Future growth depends on the successful development and commercialization of LB-100. Analyst estimates are variable and dependent on clinical trial outcomes.
Recent Initiatives: Recent initiatives include ongoing clinical trials of LB-100 in various cancer types and exploring potential partnerships.
Summary
Lixte Biotechnology is a high-risk, high-reward biotechnology company focused on developing LB-100. Success hinges on positive clinical trial results and securing partnerships. Its small size and limited financial resources pose challenges. It needs to generate positive clinical data and explore partnerships to accelerate development and commercialization.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports (where available)
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The biotechnology industry is inherently risky, and investment decisions should be made with caution.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lixte Biotechnology Holdings Inc
Exchange NASDAQ | Headquaters Pasadena, CA, United States | ||
IPO Launch date 2007-09-21 | CEO & Chairman Mr. Geordan G. Pursglove | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://lixte.com |
Full time employees 2 | Website https://lixte.com |
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.